Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Paricalcitol · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Paricalcitol Capsules, 4 mcg | EXPERIMENTAL | Paricalcitol Capsules, 4 mcg of Dr. Reddy's Laboratories Limited |
| Zemplar Capsules, 4 mcg | EXPERIMENTAL | Zemplar Capsules, 4 mcg of Abott Laboratories USA |
| Name | Type | Description |
|---|---|---|
| Paricalcitol Capsules, 4 mcg | DRUG | Paricalcitol Capsules, 4 mcg of Dr. Reddy's Laboratories Limited |
Inclusion Criteria: * Healthy, adult, human volunteers between 18 and 55 years of age (both inclusive) living in and around Ahmedabad city of western part of India. * Having a Body Mass Index (BMI) between 18.5 and 24.9 (both inclusive), calculated as weight in kg/height in m2. * Have no significan...
Paricalcitol is a small molecule drug being developed by Dr. Reddy's Laboratories Ltd. It is currently in Phase 1 clinical development. The drug has been studied in a bioequivalence trial for healthy volunteers.
Paricalcitol is being studied for use in healthy volunteers. The completed Phase 1 trial was a bioequivalence study of Paricalcitol capsules, 4 mcg, under fasting conditions. The drug's therapeutic area is classified as Other.
Paricalcitol is being developed by Dr. Reddy's Laboratories Ltd, a pharmaceutical company listed on the stock exchange under the ticker RDY. The company conducted a Phase 1 clinical trial for this drug.
Paricalcitol is in Phase 1 clinical development. The drug has completed one Phase 1 trial, which was a bioequivalence study. It is not yet approved and remains investigational.
Paricalcitol has one completed clinical trial, NCT02322632, titled "Bioequivalence Study of Paricalcitol Capsules, 4 mcg Under Fasting Conditions." This Phase 1 trial enrolled 69 healthy volunteers in India and was a controlled, randomized study.